This islet transplantation trial, supported by the National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases, and National Institute of Allergy and Infectious Diseases, have fostered development of islet transplantation as a therapeutic treatment for T1D. The aim of this Continuation Award is to complete the existing CIT islet transplant studies, and result in an improved treatment of T1D and licensure of the human islet product. Three study protocols have been developed. as they relate to each protocol are: 1. To determine the safety and efficacy of peri-transplant administration of the anti-inflammatory agent deoxyspergualin (DSG) on the engraftment and function of pancreatic islet transplants in type 1 diabetic patients (CIT Protocol 03). 2. To determine the safety and efficacy of a steroid-free, tacrolimus sparing immunosuppressive protocol in type 1 diabetic patients receiving pancreatic islet transplants (CIT Protocol 07). 3. To determine the efficacy of islet transplantation in type 1 diabetic kidney allograft recipients (CIT Protocol 06).
|Effective start/end date||9/20/12 → 7/31/17|
- University of Iowa (2U01DK070431-11)
- National Institute of Diabetes and Digestive and Kidney Diseases (2U01DK070431-11)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.